Wall Street is positive on Revance Therapeutics Inc (RVNC). On average, analysts give the stock a Strong Buy rating. The average price target is $28.111, which means analysts expect the stock to gain by 106.09% over the next twelve months. That average ranking earns the stock an Analyst Rating of 63, which is better than 63% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating RVNC a Strong Buy today. Find out what this means to you and get the rest of the rankings on RVNC!